Jenscare-B (09877) reported annual performance, achieving revenue of 90.6 million yuan in its first year of commercialization.

Jenscare-B (09877) released its annual performance by December 31, 2025, continuing to advance its global commercialization strategy for structural heart disease intervention products. During the reporting period, the group achieved revenue of 90.6 million RMB, with other income and gains of 16.6 million RMB, totaling 1.07 billion RMB. 2025 marks the first year of the company's commercial development. During the reporting period, the company continued to focus on structural heart disease intervention products, firmly implemented its internationalization strategy, and promoted the conversion of differentiated core technological achievements into value in the global market. The aortic valve replacement product Ken-Valve made rapid progress in sales and implantation in its first year of commercialization; several important products such as LuX-ValvePlus for tricuspid valve replacement and JensClip for mitral valve repair achieved clinical and commercial breakthroughs in multiple countries and regions globally. The company achieved significant revenue in its first year of commercialization, demonstrating its strong commercial operational capabilities. With the further deepening of the company's international business, stable and rapid revenue growth is expected, laying a solid foundation for the long-term sustainable development of the group. The company places innovative research and development as the core pillar, continuously strengthening its research and development layout in the field of structural heart disease intervention therapy. Through product layouts covering diseases such as tricuspid valve, aortic valve, and mitral valve, the company has formed a high-growth, comprehensive, and globally competitive core product matrix. At the same time, the company, guided by global clinical demand, continues to optimize the performance of existing products, accelerate the iterative upgrading of core products, actively explore cutting-edge technological directions and innovative pipelines, promote the research and clinical translation of multiple new products, enrich the product portfolio, meet diverse clinical needs, and inject continuous momentum for long-term development.